Anti-interferon medicines for Aicardi‑Goutières syndrome (AGS)
Efficacy and mechanisms of anti-IFN drugs in AGS treatment
This project aims to see if medicines that block interferon signaling can reduce the harmful brain inflammation that causes damage in people with Aicardi‑Goutières syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11295386 on NIH RePORTER |
What this research studies
Researchers use newly developed mouse models that reproduce the brain inflammation seen in AGS to study drugs that block interferon signaling, including newer TYK2 and TBK1 inhibitors alongside JAK inhibitors. They will measure whether these drugs stop innate immune activation in brain cells and prevent the kinds of brain injury that lead to severe disability. The team studies how the drugs work at a cellular and molecular level to understand their mechanisms in the brain. If promising, the findings would support moving toward treatments tested in people with AGS.
Who could benefit from this research
Good fit: People diagnosed with Aicardi‑Goutières syndrome, especially infants and children showing signs of active brain inflammation, would be the most relevant candidates for related future trials.
Not a fit: People without AGS or those whose brain damage is already irreversible from long-standing disease are unlikely to benefit from these investigational approaches.
Why it matters
Potential benefit: If successful, this work could lead to medicines that prevent or reduce brain inflammation and slow or stop neurological decline in AGS.
How similar studies have performed: Previous human trials of JAK inhibitors improved systemic symptoms but largely failed to reverse brain injury, while recent preclinical AGS mouse data suggest TYK2 and TBK1 inhibitors may more effectively block brain innate immune activation.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Billiar, Timothy R — University of Pittsburgh at Pittsburgh
- Study coordinator: Billiar, Timothy R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.